We are a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. As a woman-founded and led […]

Sprinklr empowers the world’s largest and most loved brands to make their customers happier. We do this with a new category of enterprise software – Unified Customer Experience Management, or Unified-CXM – that enables every customer-facing function across the front office, from Customer Care to Marketing, to collaborate across internal silos, communicate across digital channels, […]

We are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from […]

iSpecimen’s mission is to accelerate life science research and development, or R&D, with a global marketplace platform that connects researchers to subjects, specimens and associated data. Our vision is to create an “Amazon-like” global Marketplace of patients, biospecimens and data for research to improve the quality of human life.   iSpecimen is a technology-driven company […]

We are a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (“WHO”), the U.S. Centers for Disease Control and Prevention (“CDC”) and the U.S. Food and Drug Administration (“FDA”). Priority pathogens are those which require new antibiotics to address […]

(Note: This biotech company is focused on developing synthetic psychedelic compounds to treat mental health disorders, including treatment-resistant depression, anxiety and substance abuse disorder. Billionaire Peter Thiel invested $12 million in this start-up in November 2020 through Thiel Capital, his venture capital firm, as part of a $125 million private fund-raising round, CNBC reported.)  We […]

(Note: IPOScoop has NO CALL on this deal because it is NOT an IPO. This is a NASDAQ uplisting from the SIX Swiss Exchange Ltd., where the company’s stock trades under the symbol “MOLN.” On June 8, 2021, the last reported sale price was CHF 24.40, equivalent to US$27.14.)    We are a clinical biopharmaceutical […]

We are a biotechnology company dedicated to developing treatments for certain medical conditions. Two of our programs are focused on kidney disease: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb and UNI 494 were initially developed by, and licensed to us […]

DiDi is known as China’s Uber. Principal stockholders include a SoftBank Vision Fund entity, with a 21.5 percent pre-IPO stake; an Uber entity, with a 12.8 percent pre-IPO stake, and Tencent Entities, with a 6.8 percent IPO stake. This is expected to be one of the largest tech IPOs of the year. The company recently […]

We are a preclinical biotech company. We are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We have assembled a world-class team, comprising some of the foremost scientific leaders in the fields of oncology and adoptive cell therapy (ACT), including Drs. Rick Klausner, Nick Restifo, Stan […]